Key result
Recent therapeutic innovations and developing targets in acute and chronic heart failure with reduced ejection fraction are continuously changing and improving the personalized approach to the disease.
Why the study?
HFrEF remains characterized by high mortality and hospitalization rates, prompting a continuous need for treatments and reviews of recently approved drugs and developing therapeutic targets.
This review provides an overview of recently approved drugs and developing therapeutic targets for the management of acute and chronic HFrEF.
New HFrEF agents may improve stability now in selected patients; leaves open optimal sequencing and personalization as phenotypes evolve.
Heart failure with reduced ejection fraction (HFrEF) is a pathological condition still characterized by high rates of mortality and disease exacerbation frequently leading to hospitalization, thus there is a continuous need for pharmacological treatments impacting on disease stability and long-term prognosis. Moreover, the phenotype of heart failure patients is continuously changing over time, and the development of new heart failure drugs is crucial to promote a personalized and targeted approach. In recent years, several therapeutic innovations have emerged in the landscape of acute and chronic HFrEF, largely changing and improving our approach to the disease. Various studies on new drugs and experimental therapeutic approaches are ongoing. The present review discusses the latest data on both recently approved drugs and developing therapeutic targets, in order to provide a critical overview for an informed and optimal approach to such a complex disease.
No takes yet. Share an insight, caveat, or question.
Mercurio et al. (2022) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Recently approved drugs and developing therapeutic targets was evaluated. Recent therapeutic innovations and developing targets in acute and chronic heart failure with reduced ejection fraction are continuously changing and improving the personalized approach to the disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: